Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F H Messerli

Showing results (51-60 of 338) with videos related to

Pageof 34
Sort By:
Journal of Human Hypertension|October 12, 1999
. . . and losartan was no better than placeboF H Messerli
American Journal of Hypertension|January 5, 2000
Hypertension and sudden cardiac deathF H Messerli
Lancet (London, England)|September 16, 1995
Are calcium antagonists safe?F H Messerli
Journal of the American College of Cardiology|July 1, 1996
Whatever happened to the calcium antagonist controversy?F H Messerli
Circulation|March 1, 1990
Antihypertensive therapy--going to the heart of the matterF H Messerli
Blood Pressure. Supplement|January 1, 1992
Left ventricular hypertrophy as a coronary risk factorF H Messerli
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1990
Left ventricular hypertrophy, arterial hypertension and sudden deathF H Messerli
Journal of the American College of Cardiology|November 3, 2001
Doxazosin and congestive heart failureF H Messerli
Clinical Therapeutics|April 25, 2001
Antihypertensive effects of losartan and candesartanF H Messerli
Lancet (London, England)|April 7, 2000
Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialF H Messerli
Pageof 34

Showing results (51-60 of 338) with videos related to

Sort By:
Pageof 34
Journal of Human Hypertension|October 12, 1999
. . . and losartan was no better than placeboF H Messerli
American Journal of Hypertension|January 5, 2000
Hypertension and sudden cardiac deathF H Messerli
Lancet (London, England)|September 16, 1995
Are calcium antagonists safe?F H Messerli
Journal of the American College of Cardiology|July 1, 1996
Whatever happened to the calcium antagonist controversy?F H Messerli
Circulation|March 1, 1990
Antihypertensive therapy--going to the heart of the matterF H Messerli
Blood Pressure. Supplement|January 1, 1992
Left ventricular hypertrophy as a coronary risk factorF H Messerli
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1990
Left ventricular hypertrophy, arterial hypertension and sudden deathF H Messerli
Journal of the American College of Cardiology|November 3, 2001
Doxazosin and congestive heart failureF H Messerli
Clinical Therapeutics|April 25, 2001
Antihypertensive effects of losartan and candesartanF H Messerli
Lancet (London, England)|April 7, 2000
Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialF H Messerli
Pageof 34